Zevra Therapeutics (NASDAQ:ZVRA) PT Raised to $20.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price lifted by equities researchers at HC Wainwright from $18.00 to $20.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 148.14% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Finally, William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.25.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.06 on Friday. The firm has a fifty day moving average price of $7.04 and a 200-day moving average price of $5.71. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market cap of $337.34 million, a PE ratio of -5.97 and a beta of 1.94. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the previous year, the business posted ($0.15) earnings per share. Equities analysts anticipate that Zevra Therapeutics will post -1.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zevra Therapeutics news, Director Thomas Anderson acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the purchase, the director now owns 20,000 shares in the company, valued at approximately $136,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have purchased 22,000 shares of company stock valued at $140,340. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Jump Financial LLC purchased a new stake in Zevra Therapeutics in the 4th quarter worth $217,000. Armistice Capital LLC purchased a new stake in Zevra Therapeutics in the 4th quarter worth $1,755,000. Jacobs Levy Equity Management Inc. increased its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after acquiring an additional 17,557 shares in the last quarter. Virtu Financial LLC purchased a new stake in Zevra Therapeutics in the 4th quarter worth $177,000. Finally, Focus Financial Network Inc. ADV purchased a new stake in Zevra Therapeutics in the 4th quarter worth $141,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.